Commentary

Video

Dr Spigel on the Efficacy of Durvalumab Consolidation Therapy in LS-SCLC

David R. Spigel, MD, discusses findings from the phase 3 ADRIATIC trial in patients with limited-stage small cell lung cancer.

David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, discusses findings from the first planned interim analysis of the phase 3 ADRIATIC trial (NCT03703297) in patients with limited-stage small cell lung cancer (LS-SCLC).

ADRIATIC evaluated durvalumab (Imfinzi; n = 264) vs placebo (n = 266) as consolidation therapy in patients with LS-SCLC who had received prior concurrent chemoradiotherapy. The coprimary end points of the trial were overall survival (OS) and progression-free survival (PFS) by blinded independent central review, Spigel states.

This trial met both primary end points, he reports. At a median follow-up of 37.2 months (range, 0.1-60.9) in censored patients, durvalumab elicited an OS benefit over placebo. The median OS was 55.9 months (95% CI, 37.3-not evaluable) with durvalumab vs 33.4 months (95% CI, 25.5-39.9) with placebo, resulting in a 27% reduction in the risk of death (HR, 0.73; 95% CI, 0.57-0.93; P = .0104). In the durvalumab arm (n = 264), the 24- and 36-month OS rates were 68.0% and 56.5%, respectively. These values were 58.5% and 47.6%, respectively, in the placebo arm (n = 266).

Furthermore, at a median follow-up of 27.6 months (range, 0.0-55.8) in censored patients, durvalumab generated a median PFS of 16.6 months (95% CI, 10.2-28.2) vs 9.2 months (95% CI, 7.4-12.9), respectively. This translated to a 24% reduction in the risk of death or disease progression (HR, 0.76; 95% CI, 0.61-0.95; P = .0161), Spigel adds. In the durvalumab arm, the 24- and 36-month OS rates were 48.8% and 46.2%, respectively. These values were 36.1% and 34.2%, respectively, in the placebo arm.

Notably, ADRIATIC also enrolled patients to a third arm, where they received dual checkpoint inhibition with durvalumab plus the CTLA-4 inhibitor tremelimumab-actl (Imjudo), Spigel says. Future data readouts from this trial will include findings from an analysis of the durvalumab/tremelimumab arm vs the placebo arm, although those data are currently blinded, Spigel concludes.

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD